Quanterix (QTRX) AI Stock Analysis

• Market Cap: $255.50M
• Dividend Yield: N/A
• Average Volume (3M): 715.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 7.71%
• EPS Growth: -38.97%
• Country: US
• Employees: 471
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Devices
• EPS (TTM): -0.53
• Shares Outstanding: 38,829,388
• 10 Day Avg. Volume: 818,100
• 30 Day Avg. Volume: 715,607
• PEG Ratio: -1.82
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.32
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 0.35
• Enterprise Value/Gross Profit: 2.27
• Enterprise Value/Ebitda: -1.07
• 1Y Price Target: $12.33
• Price Target Upside: 85.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 56 Neutral
• Price Target: $7.00 ▲(5.11%Upside)

Quanterix's overall stock score is driven by a strong balance sheet and positive technical indicators. However, profitability issues and a challenging valuation weigh down the score. Strategic initiatives and merger synergies provide some optimism but are offset by revenue declines and macroeconomic headwinds.

Positive Factors

Cost Synergies

QTRX now expects to realize $55M in cost synergies with AKYA to maintain 2026 cash flow profitability target, driven by facility consolidation and deduplication of G&A and sales support.

Growth Opportunities

The early access program for the Simoa One platform and the expected launch of 15 new assays in 2025 could provide growth opportunities for Quanterix.

Revenue Performance

QTRX announced 1Q25 revenue of $30M, beating estimates, with product revenue leading the quarter.

Negative Factors

Integration Risks

The acquisition adds integration risks to an already challenging macro backdrop and reduces cash flexibility for QTRX.

Market Competition

It is challenging for QTRX to gain meaningful adoption in the Alzheimer's disease diagnostic market with multiple competitors entering the market and an FDA approved assay now available.

Revenue Guidance

Quanterix meaningfully lowered its 2025 revenue guidance due to expected macroeconomic headwinds, such as tariffs and U.S. academic funding weakness.

Quanterix Business Overview & Revenue Model

Company Description

Quanterix Corporation is a company operating in the biotechnology sector, specializing in advanced diagnostics. It develops and markets ultra-sensitive digital immunoassay platforms that enable researchers and clinicians to detect and quantify proteins and nucleic acids at extremely low concentrations. The company's flagship product, the Simoa (Single Molecule Array) platform, is utilized for various applications, including biomarker research, drug development, and disease diagnostics, particularly in neurological, oncological, and infectious disease fields.

How the Company Makes Money

Quanterix generates revenue primarily through the sale of its Simoa diagnostic platforms and related consumables, which are integral to its customers' research and diagnostic processes. The company also earns income by providing services such as sample testing and assay development, which support and enhance the utility of its platforms. Additionally, Quanterix engages in strategic partnerships and collaborations with pharmaceutical companies, academic institutions, and research organizations, which can lead to joint development agreements, grants, and licensing opportunities that contribute to its revenue. The company's focus on high-sensitivity diagnostics positions it to capitalize on the growing demand for precision medicine and advanced biomarker discovery.

Quanterix Financial Statement Overview

Summary

Quanterix shows strong revenue growth and a stable balance sheet with low leverage. However, significant challenges exist with profitability and cash flows, necessitating improvements in operational efficiency.

Income Statement

Quanterix shows consistent revenue growth, with a notable increase from $122.37M in 2023 to $137.42M in 2024. However, profitability metrics are concerning, with a negative EBIT margin of -38.3% in 2024 and a net profit margin of -28%. The company has struggled to translate revenue growth into profitability, which is a significant area of concern.

Balance Sheet

The company maintains a strong equity position with a debt-to-equity ratio of 0.11 and a robust equity ratio of 81.2%. However, the consistent negative net income has impacted the return on equity, which remains negative. Quanterix's strong cash position and low leverage are positive indicators of financial stability.

Cash Flow

Operating cash flow remains negative at -$35.16M for 2024, reflecting ongoing operational challenges. Free cash flow also remained negative despite a reduction in capital expenditures. The company faces challenges in converting revenue growth into positive cash flows, an area that requires attention for long-term sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
135.44M	122.37M	104.95M	110.56M	86.38M
	Gross Profit
81.12M	70.65M	46.24M	61.73M	48.18M
	EBIT
-52.62M	-44.45M	-72.36M	-58.59M	-31.58M
	EBITDA
-44.26M	-38.09M	-65.73M	-53.24M	-27.27M
	Net Income Common Stockholders
-38.53M	-32.33M	-96.70M	-57.69M	-31.53M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
289.12M	321.32M	338.74M	396.46M	181.58M
	Total Assets
406.53M	425.01M	434.20M	501.53M	271.05M
	Total Debt
37.37M	41.46M	44.10M	21.89M	30.80M
	Net Debt
-19.34M	-132.96M	-294.64M	-374.57M	-150.79M
	Total Liabilities
76.50M	78.08M	75.26M	60.58M	64.92M
	Stockholders Equity
330.04M	346.93M	358.94M	440.95M	206.13M
Cash Flow		Free Cash Flow
-38.53M	-22.69M	-60.00M	-61.52M	-27.30M
	Operating Cash Flow
-35.16M	-18.90M	-48.27M	-47.91M	-23.36M
	Investing Cash Flow
-82.27M	-148.40M	-11.21M	-6.34M	-626.00K
	Financing Cash Flow
456.00K	2.69M	2.31M	270.80M	96.24M

Quanterix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.66
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTRX, the sentiment is Positive. The current price of 6.66 is above the 20-day moving average (MA) of 5.19, above the 50-day MA of 5.40, and below the 200-day MA of 9.45, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 65.84 is Neutral, neither overbought nor oversold. The STOCH value of 66.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QTRX.

Quanterix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	76 Outperform	$167.14M	25.13	16.56%	―	14.85%	64.96%
CERS	65 Neutral	$275.27M	―	-36.14%	―	13.06%	41.50%
QTRX	56 Neutral	$255.50M	―	-14.51%	―	7.71%	-38.97%
RCEL	55 Neutral	$158.34M	―	-407.50%	―	32.24%	-66.93%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
ANIK	47 Neutral	$165.64M	―	-20.42%	―	-18.80%	26.16%
LUNG	46 Neutral	$136.88M	―	-60.68%	―	19.84%	5.77%

Quanterix Corporate Events

Quanterix Approves Cost-Reduction Plan Amidst Strategic Moves

On May 7, 2025, Quanterix‘s Board of Directors approved a cost-reduction plan to save $15 million in 2025, with annualized savings of $30 million. This includes a significant reduction in workforce, expected to be completed by the end of the second quarter of 2025. Additionally, Quanterix announced a strategic move to integrate its Simoa® ONE assay kits with over 20,000 flow cytometers globally, enhancing its market reach and reducing the need for new equipment purchases. The company also reported a net loss for the first quarter of 2025 but is implementing measures to achieve positive cash flow by 2026, including a merger with Akoya Biosciences, expected to close in June 2025.

The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Quanterix Revises Merger Terms with Akoya Biosciences

On April 28, 2025, Quanterix Corporation announced an amended merger agreement with Akoya Biosciences, revising the terms of their previously announced merger. Under the new terms, Quanterix will issue fewer shares and pay $20 million in cash to Akoya shareholders, with Quanterix shareholders owning 84% of the combined entity. This strategic move aims to create value for shareholders and leverage combined resources to drive synergies and expedite profitability. The merger is expected to close in the second quarter of 2025, pending Akoya shareholder approval and other customary conditions.

Quanterix Appoints William Donnelly as New Chairman

On March 24, 2025, Quanterix Corporation appointed William P. Donnelly as the new Chairman of the Board, succeeding Martin D. Madaus, Ph.D. This change follows Dr. Madaus’s decision to resign after receiving less than a majority of votes for his reelection at the 2024 annual meeting. The Board and its Nominating and Governance Committee reviewed the voting results and considered feedback from stockholders before deciding on the leadership change. Dr. Madaus’s resignation is not due to any disagreements with the company, and he is acknowledged for his service.